Literature DB >> 32812686

GPR91, a critical signaling mechanism in modulating pathophysiologic processes in chronic illnesses.

Xinyi Li1, Li Xie1, Xiangli Qu2,3, Bangyi Zhao4, Wei Fu4, Beili Wu2,3, Jian Wu1,5,6.   

Abstract

Succinate receptor GPR91 is one of G protein-coupled receptors (GPCRs), and is expressed in a variety of cell types and tissues. Succinate is its natural ligand, and its activation represents that an intrinsic metabolic intermediate exerts a regulatory role on many critical life processes involving pathophysiologic mechanisms, such as innate immunity, inflammation, tissue repair, and oncogenesis. With the illustration of 3-dimensional crystal structure of the receptor and discovery of its antagonists, it is possible to dissect the succinate-GPR91-G protein signaling pathways in different cell types under pathophysiological conditions. Deep understanding of the GPR91-ligand binding mode with various agonists and antagonists would aid in elucidating the molecular basis of a spectrum of chronic illnesses, such as hypertension, diabetes, and their renal and retina complications, metabolic-associated fatty liver diseases, such as nonalcoholic steatohepatitis and its fibrotic progression, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), age-related macular degeneration, rheumatoid arthritis, and progressive behaviors of malignancies. With better delineation of critical regulatory role of the succinate-GPR91 axis in these illnesses, therapeutic intervention may be developed by specifically targeting this signaling pathway with small molecular antagonists or other strategies.
© 2020 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  G protein-coupled receptor; SUCNR1; innate immunity; metabolic regulation; succinate

Year:  2020        PMID: 32812686     DOI: 10.1096/fj.202001037R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

1.  The apoptotic efficacy of succinic acid on renal cancer cell lines.

Authors:  Goksu Kasarci; Baris Ertugrul; Elif Sinem Iplik; Bedia Cakmakoglu
Journal:  Med Oncol       Date:  2021-10-23       Impact factor: 3.064

2.  Western Diet Decreases the Liver Mitochondrial Oxidative Flux of Succinate: Insight from a Murine NAFLD Model.

Authors:  Pavla Staňková; Otto Kučera; Eva Peterová; Moustafa Elkalaf; David Rychtrmoc; Jan Melek; Miroslav Podhola; Veronika Zubáňová; Zuzana Červinková
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

3.  Mitochondrial Ultrastructure and Activity Are Differentially Regulated by Glycolysis-, Krebs Cycle-, and Microbiota-Derived Metabolites in Monocytes.

Authors:  C Angélica Pérez-Hernández; M Maximina Bertha Moreno-Altamirano; Edgar O López-Villegas; Egle Butkeviciute; Mohammad Ali; Barbara Kronsteiner; Susanna J Dunachie; Hazel M Dockrell; Steven G Smith; F Javier Sánchez-García
Journal:  Biology (Basel)       Date:  2022-07-28

Review 4.  Metabolite G-Protein Coupled Receptors in Cardio-Metabolic Diseases.

Authors:  Derek Strassheim; Timothy Sullivan; David C Irwin; Evgenia Gerasimovskaya; Tim Lahm; Dwight J Klemm; Edward C Dempsey; Kurt R Stenmark; Vijaya Karoor
Journal:  Cells       Date:  2021-11-29       Impact factor: 7.666

5.  SUCNR1 Mediates the Priming Step of the Inflammasome in Intestinal Epithelial Cells: Relevance in Ulcerative Colitis.

Authors:  Cristina Bauset; Lluis Lis-Lopez; Sandra Coll; Laura Gisbert-Ferrándiz; Dulce C Macias-Ceja; Marta Seco-Cervera; Francisco Navarro; Juan V Esplugues; Sara Calatayud; Dolores Ortiz-Masia; Maria D Barrachina; Jesús Cosín-Roger
Journal:  Biomedicines       Date:  2022-02-24

6.  Succinate/IL-1β Signaling Axis Promotes the Inflammatory Progression of Endothelial and Exacerbates Atherosclerosis.

Authors:  Jingwen Xu; Yabing Zheng; Yaqing Zhao; Yujiao Zhang; Huilin Li; An Zhang; Xuehan Wang; Weizong Wang; Yinglong Hou; Jiangrong Wang
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.